BR112021024333A2 - Composições terapêuticas compreendendo compostos de n,n-dimetiltriptamina deuterado ou parcialmente deuterado - Google Patents
Composições terapêuticas compreendendo compostos de n,n-dimetiltriptamina deuterado ou parcialmente deuteradoInfo
- Publication number
- BR112021024333A2 BR112021024333A2 BR112021024333A BR112021024333A BR112021024333A2 BR 112021024333 A2 BR112021024333 A2 BR 112021024333A2 BR 112021024333 A BR112021024333 A BR 112021024333A BR 112021024333 A BR112021024333 A BR 112021024333A BR 112021024333 A2 BR112021024333 A2 BR 112021024333A2
- Authority
- BR
- Brazil
- Prior art keywords
- dimethyltryptamine
- deuterated
- compositions
- partially
- present
- Prior art date
Links
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical class C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 title abstract 12
- 239000000203 mixture Substances 0.000 title abstract 7
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
composições terapêuticas compreendendo compostos de n,ndimetiltriptamina deuterado ou parcialmente deuterado. a presente invenção refere-se a composições compreendendo n,n-dimetiltriptamina, n,n-dimetiltriptamina deuterado e/ou n,n-dimetiltriptamina parcialmente deuterado. em particular, a presente invenção refere-se a composições compreendendo a combinação de n,n-dimetiltriptamina e 2% ou mais em peso de um ou mais composto de n,n-dimetiltriptamina deuterado selecionado a partir de a,a-dideutero-n,n-dimetiltriptamina e a,a,ß,ß-tetradeutero-n,n-dimetiltriptamina. adicionalmente e alternativamente as composições da presente invenção compreende uma combinação de n,n-dimetiltriptamina e 2% ou mais em peso de um ou mais composto de n,n-dimetiltriptamina parcialmente deuterado selecionado a partir de a,ß,ß-trideutero-n,n-dimetiltriptamina, a,ß-dideutero-n,n-dimetiltriptamina, e a-deutero-n,n-dimetiltriptamina. também são fornecidos métodos de síntese de composições da presente invenção, e métodos de uso de composições presentemente descritas em tratamento de transtornos psiquiátricos ou psicocognitivos, tais como transtorno depressivo maior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024333A2 true BR112021024333A2 (pt) | 2022-02-08 |
Family
ID=67385960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024333A BR112021024333A2 (pt) | 2019-06-03 | 2020-06-02 | Composições terapêuticas compreendendo compostos de n,n-dimetiltriptamina deuterado ou parcialmente deuterado |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12076311B2 (pt) |
| EP (2) | EP3826632B1 (pt) |
| JP (1) | JP7523474B2 (pt) |
| KR (2) | KR20240142567A (pt) |
| CN (1) | CN114096246A (pt) |
| AU (1) | AU2020286709B2 (pt) |
| BR (1) | BR112021024333A2 (pt) |
| CA (2) | CA3142290A1 (pt) |
| DK (1) | DK3826632T3 (pt) |
| EA (1) | EA202193338A1 (pt) |
| ES (1) | ES2922101T3 (pt) |
| GB (4) | GB201907871D0 (pt) |
| HR (1) | HRP20220837T8 (pt) |
| HU (1) | HUE059439T2 (pt) |
| IL (1) | IL288617B1 (pt) |
| MX (1) | MX2021014728A (pt) |
| PL (1) | PL3826632T3 (pt) |
| PT (1) | PT3826632T (pt) |
| TW (1) | TW202210075A (pt) |
| WO (1) | WO2020245133A1 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022005399A (es) * | 2019-11-07 | 2022-07-05 | Small Pharma Ltd | Compuestos. |
| KR20220137085A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| PL3902541T3 (pl) * | 2020-06-02 | 2022-11-14 | Small Pharma Ltd | Kompozycje terapeutyczne zawierające deuterowane lub częściowo deuterowane związki n,n-dimetyltryptaminy |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| EP4149460A1 (en) * | 2020-06-02 | 2023-03-22 | Small Pharma Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022117359A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4255422A1 (en) | 2020-12-03 | 2023-10-11 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| MX2023010316A (es) * | 2021-03-02 | 2023-11-09 | Mindset Pharma Inc | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| KR20240000516A (ko) * | 2021-04-26 | 2024-01-02 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 조성물 및 방법 |
| JP2024516279A (ja) * | 2021-05-05 | 2024-04-12 | カレ ケミカル テクノロジーズ インコーポレイテッド | 触媒トリプタミンプロセスおよび前駆体 |
| AU2022277515A1 (en) * | 2021-05-17 | 2023-10-19 | Cybin Irl Limited | Formulations of psilocybin |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
| KR20240019152A (ko) | 2021-06-09 | 2024-02-14 | 아타이 테라퓨틱스, 인크. | 신규 전구약물 및 디메틸트립타민의 접합체 |
| AU2022328217A1 (en) * | 2021-08-12 | 2024-03-14 | Kuleon Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| WO2023028091A1 (en) * | 2021-08-23 | 2023-03-02 | Alexander Shulgin Research Institute | Deuterated empathogens |
| IL311051A (en) * | 2021-08-23 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Fluorinated empathogens |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| EP4159201A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| WO2023076135A1 (en) * | 2021-10-29 | 2023-05-04 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| KR20240110836A (ko) | 2021-11-18 | 2024-07-16 | 사이빈 유케이 리미티드 | 주사용 및 흡입용 제제 |
| US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168022A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocybin |
| WO2023186867A1 (en) * | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| AU2023269880A1 (en) | 2022-05-10 | 2024-01-18 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| WO2024200710A1 (en) | 2023-03-31 | 2024-10-03 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| EP0593513B1 (en) | 1991-06-21 | 1998-10-28 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like receptors or 5-ht2 receptor agonistes |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| WO2001097779A2 (en) | 2000-06-16 | 2001-12-27 | Rtp Pharma Inc. | Improved injectable dispersions of propofol |
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| CA2666149A1 (en) | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| AU2008310883A1 (en) | 2007-10-09 | 2009-04-16 | Hamann, Mark T | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US10933073B2 (en) | 2017-02-09 | 2021-03-02 | Caamtech Llc | Compositions and methods comprising a psilocybin derivative |
| WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| CN109251151A (zh) * | 2017-07-12 | 2019-01-22 | 北京广为医药科技有限公司 | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 |
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| US11117870B2 (en) | 2017-11-01 | 2021-09-14 | Drexel University | Compounds, compositions, and methods for treating diseases |
| AU2020225766A1 (en) | 2019-02-22 | 2021-08-19 | GH Research Ireland Limited | Compositions comprising 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for use in treating mental disorders |
| PE20220015A1 (es) | 2019-02-22 | 2022-01-11 | Gh Res Ireland Limited | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresion |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
| JP2022523774A (ja) | 2019-02-27 | 2022-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022005399A (es) | 2019-11-07 | 2022-07-05 | Small Pharma Ltd | Compuestos. |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| AU2021334933B2 (en) | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| EP4221682A2 (en) | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US20240016782A1 (en) | 2020-12-01 | 2024-01-18 | Small Pharma Ltd. | Inhalable formulations |
| WO2022117359A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US20230149293A1 (en) | 2021-11-18 | 2023-05-18 | Small Pharma Ltd. | Injectable and inhalable formulations |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 JP JP2021571882A patent/JP7523474B2/ja active Active
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 CN CN202080050439.9A patent/CN114096246A/zh active Pending
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 US US17/616,345 patent/US12076311B2/en active Active
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 KR KR1020247030292A patent/KR20240142567A/ko active Search and Examination
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en unknown
- 2020-06-02 CA CA3142290A patent/CA3142290A1/en active Pending
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 IL IL288617A patent/IL288617B1/en unknown
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 EP EP22173907.1A patent/EP4062910A1/en active Pending
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active IP Right Cessation
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TW202210075A/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024333A2 (pt) | Composições terapêuticas compreendendo compostos de n,n-dimetiltriptamina deuterado ou parcialmente deuterado | |
| MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
| MX2020013853A (es) | Compuestos innovadores. | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| CY1116894T1 (el) | Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| MY196791A (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| CL2020002604A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| EA202091340A1 (ru) | Способ получения соединений "лекарственное средство-линкер" | |
| MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| PH12020550594A1 (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| MX2020010425A (es) | Composicion isotopicamente modificada y sus usos terapeuticos. | |
| MX2024001889A (es) | Compuestos deuterados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: SMALL PHARMA LTD (GB) |